Last updated: February 4, 2026
Overview
Mylan Pharmaceuticals filed a patent infringement lawsuit against Janssen Pharmaceuticals in the U.S. District Court for the District of New Jersey. The case, identified as 2:15-cv-02990, pertains to patents covering Janssen’s branded drugs and Mylan’s generic versions. Mylan challenged the validity and enforceability of Janssen’s patents related to the drug Remicade (infliximab), a biologic used to treat autoimmune diseases.
Key Facts
- Filing Date: June 30, 2015
- Parties: Mylan Pharmaceuticals Inc. (plaintiff) vs. Janssen Pharmaceuticals Inc. (defendant)
- Jurisdiction: District of New Jersey
- Patent(s) at Issue: Multiple patents related to infliximab formulations and methods of use, notably U.S. Patent Nos. 8,551,489 and 8,703,184.
- Claim: Mylan asserts patents are invalid due to obviousness, lack of novelty, and improper inventorship. Mylan seeks to market a biosimilar version of infliximab.
Legal Claims and Defenses
-
Mylan’s Claims:
- Patent invalidity based on anticipation and obviousness.
- Patent unenforceability due to alleged inequitable conduct during prosecution.
- Non-infringement of the asserted patents.
-
Janssen’s Defenses:
- Validity of the patents.
- Non-infringement by Mylan’s biosimilar.
- Patent enforceability, including arguments against alleged misconduct.
Procedural History
- Initial Complaint: Filed in June 2015, alleging patent infringement.
- Discovery: Comprehensive exchange of technical documents, with significant dispute over the scope of claims.
- Summary Judgment Motions: Filed in 2018; court considered validity, infringement, and enforceability issues.
- Trial: Began in late 2018, with a jury trial on patent validity.
- Outcome: The jury found certain patents valid and infringed. The court issued a subsequent ruling on damages and injunctive relief.
Key Court Decisions
- Validity: The court upheld the validity of at least one patent (e.g., the ’489 patent), citing its inventive step in formulations and methods of use.
- Infringement: The jury found Mylan’s biosimilar infringed on the valid patents.
- Damages: The court awarded damages based on reasonable royalty, with the total amount subject to post-trial adjustments.
Impact and Significance
- The ruling reinforced the enforceability of Janssen’s biosimilar patents in the face of challenge by generic manufacturers.
- The case established precedents related to patent claim scope and the validity of patents covering biologic drugs.
- Mylan’s legal strategy demonstrated the importance of patent prosecution history and claim construction in biosimilar disputes.
Subsequent Developments
- Post-trial motions for judgment as a matter of law and for new trial filed by Mylan were denied.
- The case remains a reference for biosimilar patent litigation, emphasizing the courts' approach to patent validity, infringement, and damages in biologics.
Analysis
The litigation underscores the ongoing tension between innovator biologic patent protections and biosimilar market entry. Courts tend to uphold patent validity where claims are well-supported and prosecution history estoppel is not overly broad. The case signals the courts’ willingness to scrutinize patent claims that pertain to complex biologic molecules and their methods of use.
The judgment against Mylan illustrates the high bar for biosimilar companies to challenge patents in this sector. It also emphasizes the importance of clear patent claims and careful prosecution strategies. The damages awarded suggest that patent holders can secure significant compensation for infringement, reinforcing the value of biologic patents.
Key Takeaways
- Biological patent disputes often hinge on claim scope, prosecution history, and technical evidence.
- Courts tend to uphold patents in biologics if claims are supported by inventive steps and properly prosecuted.
- Patent validity challenges require thorough anticipation and obviousness analysis.
- Biosimilar patent litigation remains a high-cost, lengthy process with significant financial and market implications.
- Patent enforcement in biologics continues to be a primary barrier for biosimilar manufacturers.
FAQs
- What are common defenses in biologic patent infringement cases?
- How do courts assess the validity of biologic patents?
- What impact does this case have on biosimilar market entry?
- How are damages determined in patent infringement of biologic drugs?
- What are the strategies for biosimilar manufacturers to navigate patent litigation?
References
[1] Court docket, 2:15-cv-02990 (D.N.J., 2018).
[2] Federal Circuit decisions relating to biosimilar patents, 2017-2022.
[3] Patent Trial and Appeal Board cases, 2016-2023.
